Last reviewed · How we verify
Aliskiren + Valsartan
Aliskiren and valsartan work together to lower blood pressure by blocking the renin-angiotensin-aldosterone system at two different points: aliskiren directly inhibits renin, while valsartan blocks angiotensin II receptors.
Aliskiren and valsartan work together to lower blood pressure by blocking the renin-angiotensin-aldosterone system at two different points: aliskiren directly inhibits renin, while valsartan blocks angiotensin II receptors. Used for Hypertension.
At a glance
| Generic name | Aliskiren + Valsartan |
|---|---|
| Sponsor | HeartDrug Research LLC |
| Drug class | Direct renin inhibitor + angiotensin II receptor blocker combination |
| Target | Renin and AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aliskiren is a direct renin inhibitor that prevents the initial step of the renin-angiotensin-aldosterone system (RAAS), reducing the formation of angiotensin II. Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and other tissues. Together, they provide dual RAAS inhibition to achieve greater blood pressure reduction than either agent alone.
Approved indications
- Hypertension
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Renal impairment
- Hypotension
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients (PHASE3)
- Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance (NA)
- Aliskiren on Retinal Vasculature Treatment Study (PHASE3)
- Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure (PHASE3)
- A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients (PHASE3)
- Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients (PHASE2)
- Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aliskiren + Valsartan CI brief — competitive landscape report
- Aliskiren + Valsartan updates RSS · CI watch RSS
- HeartDrug Research LLC portfolio CI